Mechanisms of GalTKO Lung Xenograft Injury

GalTKO 肺异种移植损伤的机制

基本信息

  • 批准号:
    7901325
  • 负责人:
  • 金额:
    $ 34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2011-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: Antibodies directed at various targets (especially Gal al,3Gal) and complement are pivotal mediators of hyperacute rejection of the heart, lung, and other organs. However in pig-to-human and pig-to-non-human primate models, we have consistently found that potent complement regulation coupled with efficient removal of anti-pig antibody is associated with rapid dysfunction of lung xenografts. Thus hyperacute lung rejection (HALR) is mediated by mechanisms in addition to those that cause hyperacute rejection of other organs. This paradigm is reinforced by the preliminary studies, where three GalT-KO swine lungs perfused ex vivo retained their function for an average of 2 hours (60, 134, and 170 minutes), far longer than controls (<10 minutes). Failure was due to sudden, rapid increase in pulmonary vascular resistance. Although biopsies obtained at 10 and 30 minutes of perfusion were histologically unremarkable, intravascular thrombi and capillary congestion were observed at graft failure, despite anticoagulation with high-dose heparin. Coagulation pathway activation (Fl+2) was delayed but not prevented, platelet activation (thrombospondin release) was not attenuated, and over 70% of platelets in the perfusate were sequestered in the lung within minutes of initiating perfusion. Complement activation and deposition in the lung, while reduced, were not prevented. Based on these observations and our previous work demonstrating pivotal roles for thrombin, platelets, complement, and pulmonary intravascular macrophages in hyperacute rejection of Gal+ lungs, we hypothesize that dysregulated intravascular coagulation and residual complement activation are the principle cause of acute injury of GalT KO pig lung xenograft. To test this hypothesis, a combination of genetic (GalTKO lungs expressing human tissue factor pathway inhibitor or decay accelerating factor) and pharmacologic approaches (specific platelet receptor, thrombin, or complement inhibitors) will be used in an established ex vivo perfusion model. Approaches that yield optimal lung function ex vivo will then be validated in vivo in a life-supporting pig-to-baboon lung xenograft model. As a result of the studies proposed, we anticipate that hyperacute lung rejection will be successfully prevented for the first time using primarily donor-directed, mechanism-based strategies to consistently achieve life-supporting function of a pig lung in a baboon, allowing subsequent immunologic barriers to be addressed in this organ system.
产品说明:针对各种靶标(尤其是Gal al、3Gal)和补体的抗体是心脏、肺和其它器官的超急性排斥的关键介质。然而,在猪-人和猪-非人灵长类动物模型中,我们一致发现,有效的补体调节加上抗猪抗体的有效去除与肺异种移植物的快速功能障碍相关。因此,超急性肺排斥反应(HALR)是介导的机制,除了那些引起其他器官的超急性排斥反应。 该范例通过初步研究得到加强,其中离体灌注的三个GalT-KO猪肺平均保留其功能2小时(60、134和170分钟),远长于对照(<10分钟)。失败是由于肺血管阻力突然快速增加。尽管在灌注10分钟和30分钟时获得的活检在组织学上不显著,但在移植物衰竭时观察到血管内血栓和毛细血管充血,尽管使用了高剂量肝素抗凝。凝血途径活化(F1 +2)被延迟但未被阻止,血小板活化(血小板反应蛋白释放)未减弱,并且灌注液中超过70%的血小板在开始灌注的几分钟内被隔离在肺中。肺中的补体激活和沉积虽然减少,但没有被阻止。基于这些观察结果和我们先前的工作证明凝血酶、血小板、补体和肺血管内巨噬细胞在Gal+肺的超急性排斥反应中的关键作用,我们假设血管内凝血失调和残余补体激活是GalT KO猪肺异种移植物急性损伤的主要原因。 为了检验这一假设,将在已建立的离体灌注模型中使用遗传(表达人组织因子途径抑制剂或衰变加速因子的GalTKO肺)和药理学方法(特异性血小板受体、凝血酶或补体抑制剂)的组合。然后将在维持生命的猪-狒狒肺异种移植模型中对离体产生最佳肺功能的方法进行体内验证。由于提出的研究,我们预计,超急性肺排斥反应将首次成功地预防,主要使用供体导向的,基于机制的策略,以持续实现狒狒猪肺的生命支持功能,允许随后的免疫屏障在这个器官系统中得到解决。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard N Pierson其他文献

Erratum to: Physiological models of body composition and human obesity
  • DOI:
    10.1186/1743-7075-6-7
  • 发表时间:
    2009-02-16
  • 期刊:
  • 影响因子:
    4.100
  • 作者:
    David G Levitt;Steven B Heymsfield;Richard N Pierson;Sue A Shapses;John G Kral
  • 通讯作者:
    John G Kral
Determinants of Bone Mineral in Prepubertal Children: Gender, Ethnicity, Age, Weight, and Height
青春期前儿童骨矿物质的决定因素:性别、种族、年龄、体重和身高
  • DOI:
    10.1203/00006450-199904020-00541
  • 发表时间:
    1999-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Mary Horlick;John Thornton;Jack Wang;Barbara Fedun;Lenore S Levine;Richard N Pierson
  • 通讯作者:
    Richard N Pierson
Energy balance, viral replication and growth in HIV-infected children† 558
艾滋病病毒感染儿童的能量平衡、病毒复制和生长† 558
  • DOI:
    10.1203/00006450-199804001-00579
  • 发表时间:
    1998-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Stephen M Arpadi;Patricia A Cuff;Donald P Kotler;Marukh Bamji;Utpaul Maitra;Michael Lange;Jack Wang;Richard N Pierson
  • 通讯作者:
    Richard N Pierson

Richard N Pierson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard N Pierson', 18)}}的其他基金

Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft Tolerance
项目 3:增强共刺激阻断以实现临床相关的同种异体移植心脏耐受性
  • 批准号:
    10457402
  • 财政年份:
    2021
  • 资助金额:
    $ 34万
  • 项目类别:
Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft Tolerance
项目 3:增强共刺激阻断以实现临床相关的同种异体移植心脏耐受性
  • 批准号:
    10270362
  • 财政年份:
    2021
  • 资助金额:
    $ 34万
  • 项目类别:
Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft Tolerance
项目 3:增强共刺激阻断以实现临床相关的同种异体移植心脏耐受性
  • 批准号:
    10673082
  • 财政年份:
    2021
  • 资助金额:
    $ 34万
  • 项目类别:
CRISPR-Modified Cardiac Xenograft Transplantation
CRISPR 改良心脏异种移植
  • 批准号:
    10033905
  • 财政年份:
    2020
  • 资助金额:
    $ 34万
  • 项目类别:
CRISPR-Modified Cardiac Xenograft Transplantation
CRISPR 改良心脏异种移植
  • 批准号:
    10188418
  • 财政年份:
    2020
  • 资助金额:
    $ 34万
  • 项目类别:
CRISPR-Modified Cardiac Xenograft Transplantation
CRISPR 改良心脏异种移植
  • 批准号:
    10403525
  • 财政年份:
    2020
  • 资助金额:
    $ 34万
  • 项目类别:
CRISPR-Modified Cardiac Xenograft Transplantation
CRISPR 改良心脏异种移植
  • 批准号:
    10632137
  • 财政年份:
    2020
  • 资助金额:
    $ 34万
  • 项目类别:
Coagulation Control To Protect Gaitko Lung and Liver Xenografts
凝血控制保护 Gaitko 肺和肝异种移植物
  • 批准号:
    8009659
  • 财政年份:
    2010
  • 资助金额:
    $ 34万
  • 项目类别:
Immunomodulation for Heart Allograft Tolerance
心脏同种异体移植耐受的免疫调节
  • 批准号:
    7918484
  • 财政年份:
    2009
  • 资助金额:
    $ 34万
  • 项目类别:
Immunomodulation for Heart Allograft Tolerance
心脏同种异体移植耐受的免疫调节
  • 批准号:
    7002147
  • 财政年份:
    2005
  • 资助金额:
    $ 34万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了